Efficacy and Safety of Laggera Pterodonta in Children aged <=24 months with acute bronchiolitis: a randomized controlled trial
|
注册号: Registration number: |
ChiCTR-TRC-12002677 |
|
最近更新日期: Date of Last Refreshed on: |
2015-11-24 20:18:55 |
|
注册时间: Date of Registration: |
2011-11-08 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
臭灵丹合剂治疗儿童毛细支气管炎的有效性和安全性研究 |
|
Public title: |
Efficacy and Safety of Laggera Pterodonta in Children aged <=24 months with acute bronchiolitis: a randomized controlled trial |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
臭灵丹合剂治疗≤24 月儿童毛细支气管炎的有效性和安全性研究:随机对照试验 |
|
Scientific title: |
Efficacy and Safety of Laggera Pterodonta in Children aged <=24 months with acute bronchiolitis: a randomized controlled trial |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
尚晓丽 |
研究负责人: |
夏晓玲 |
|
Applicant: |
Xiaoli Shang |
Study leader: |
Xiaoling Xia |
|
申请注册联系人电话: Applicant telephone: |
+86 13708419461 |
研究负责人电话: Study leader's telephone: |
+86 13908712443 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
+86 0871 5327555 |
|
|
申请注册联系人电子邮件: Applicant E-mail: |
sophieshang101@hotmail.com |
研究负责人电子邮件: Study leader's E-mail: |
xxl5256@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
云南省昆明市滇缅大道374号 昆明医科大学第二附属医院 儿科 |
研究负责人通讯地址: |
云南省昆明市滇缅大道374号 昆明医科大学第二附属医院 儿科 |
|
Applicant address: |
374 Dianmian Road, Kunming, Yunnan |
Study leader's address: |
374 Dianmian Road, Kunming, Yunnan |
|
申请注册联系人邮政编码: Applicant postcode: |
650101 |
研究负责人邮政编码: Study leader's postcode: |
650101 |
|
申请人所在单位: |
昆明医科大学第二附属医院 |
||
|
Applicant's institution: |
The Second Affiliated Hospital of Kuming Medical University |
||
|
研究负责人所在单位: |
|
||
|
Affiliation of the Leader: |
|
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
[2012]伦审字(23)号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
|
|
批准本研究的伦理委员会名称: |
昆明医科大学第二附属医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Ethical Committee of the Second Affiliated Hospital of Kuming Medical University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2012-09-25 00:00:00 |
||
|
伦理委员会联系人: |
|
||
|
Contact Name of the ethic committee: |
|
||
|
伦理委员会联系地址: |
|
||
|
Contact Address of the ethic committee: |
|
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
昆明医科大学第二附属医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The Second Affiliated Hospital of Kuming Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
云南省昆明市滇缅大道374号 昆明医科大学第二附属医院 儿科 |
||||||||||||||||||||||
|
Primary sponsor's address: |
374 Dianmian Road, Kunming, Yunnan |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
云南省卫生厅 |
||||||||||||||||||||||
|
Source(s) of funding: |
Yunnan Provincial Bureau of Health |
||||||||||||||||||||||
|
Target disease: |
Acute bronchiolitis |
||||||||||||||||||||||
|
Target disease code: |
ICD10-J21 |
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
上市后药物 | ||||||||||||||||||||||
|
Study phase: |
4 |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
1. 评价臭灵丹合剂治疗儿童毛细支气管炎的有效性 2. 评价臭灵丹合剂治疗儿童毛细支气管炎的安全性 |
||||||||||||||||||||||
|
Objectives of Study: |
1. To evaluate the efficacy of Laggera Pterodonta mixture on the clinical outcomes of admitted children with acute bronchiolits; 2. To assess the safety and side effects of Laggera Pterodonta mixture in admitted children with acute bronchiolits. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
臭灵丹, 橙皮酊,水 |
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
Laggera, Pterodonta Orange tincture water |
||||||||||||||||||||||
|
纳入标准: |
1. 首次喘息,临床诊断为毛细支气管炎的3~24月住院患儿。 |
||||||||||||||||||||||
|
Inclusion criteria |
1. Admitted children aged 3~24 months clinically diagnosed as acute bronchiolitis with the first episode of wheezing from October 2012 to September 2013; |
||||||||||||||||||||||
|
排除标准: |
1. 患有慢性心肺疾病(如先天性心脏病、支气管肺发育不良、肺部囊性纤维化等)的儿童。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Those who had any chronic cardiopulmonary diseases such as congenital heart diseases, cystic fibrosis, bronchopulmonary dysplasia, or immunodeficiency; |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2012-11-01 00:00:00至 To 2013-11-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2012-11-01 00:00:00 至 To 2013-10-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
结束 /Completed |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
本研究采取区组随机化,每个区组由4个随机号组成,这一区组随机化设计和随机号的生成,由不参与本研究的统计学家使用统计学R软件独立完成 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
A statistician who is not involved in this clinical trial performed the block randomization(block si |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
|
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
|
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
|
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
|
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
|
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |